Brooktree Capital Management Acquires Shares of 10,183 DexCom, Inc. (NASDAQ:DXCM)

Brooktree Capital Management bought a new position in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 10,183 shares of the medical device company's stock, valued at approximately $683,000. DexCom accounts for about 0.6% of Brooktree Capital Management's holdings, making the stock its 22nd largest holding.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in DXCM. Migdal Insurance & Financial Holdings Ltd. acquired a new position in DexCom in the 2nd quarter valued at $25,000. Sachetta LLC increased its stake in shares of DexCom by 255.2% during the second quarter. Sachetta LLC now owns 238 shares of the medical device company's stock worth $27,000 after acquiring an additional 171 shares during the period. Crewe Advisors LLC purchased a new position in DexCom during the first quarter worth about $29,000. Riverview Trust Co raised its holdings in DexCom by 100.4% during the third quarter. Riverview Trust Co now owns 463 shares of the medical device company's stock worth $31,000 after purchasing an additional 232 shares in the last quarter. Finally, DT Investment Partners LLC boosted its holdings in DexCom by 492.2% in the 2nd quarter. DT Investment Partners LLC now owns 379 shares of the medical device company's stock valued at $43,000 after purchasing an additional 315 shares in the last quarter. Hedge funds and other institutional investors own 97.75% of the company's stock.

Insider Transactions at DexCom

In related news, EVP Sadie Stern sold 426 shares of the stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $29,457.90. Following the completion of the sale, the executive vice president now owns 75,451 shares of the company's stock, valued at approximately $5,217,436.65. This represents a 0.56 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Jacob Steven Leach sold 746 shares of the firm's stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $51,585.90. Following the completion of the transaction, the chief operating officer now owns 264,915 shares in the company, valued at $18,318,872.25. The trade was a 0.28 % decrease in their position. The disclosure for this sale can be found here. Insiders own 0.30% of the company's stock.

Analysts Set New Price Targets

Several analysts have recently commented on the company. Raymond James reduced their price target on DexCom from $115.00 to $99.00 and set a "strong-buy" rating for the company in a report on Friday, October 25th. UBS Group decreased their target price on shares of DexCom from $163.00 to $95.00 and set a "buy" rating on the stock in a research report on Friday, July 26th. Robert W. Baird increased their price target on shares of DexCom from $80.00 to $82.00 and gave the company a "neutral" rating in a report on Monday, August 5th. Morgan Stanley decreased their price objective on shares of DexCom from $120.00 to $75.00 and set an "equal weight" rating on the stock in a report on Friday, July 26th. Finally, Leerink Partners dropped their target price on shares of DexCom from $90.00 to $87.00 and set an "outperform" rating for the company in a report on Friday, October 25th. Seven investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, DexCom presently has a consensus rating of "Moderate Buy" and a consensus target price of $104.59.

DexCom Trading Up 3.0 %

DexCom stock traded up $2.15 during trading on Thursday, hitting $74.68. The company's stock had a trading volume of 4,516,872 shares, compared to its average volume of 3,921,167. The stock's fifty day moving average is $69.77 and its 200 day moving average is $92.14. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46. DexCom, Inc. has a 1-year low of $62.34 and a 1-year high of $142.00. The stock has a market capitalization of $29.17 billion, a price-to-earnings ratio of 43.29, a P/E/G ratio of 2.28 and a beta of 1.17.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.